Improved survival for patients with follicular lymphoma

Journal of Clinical Oncology

Volumn 23, Issue 22, 2005, Pages 4830-4831

  Lister, T Andrew ^a  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANTINEOPLASTIC AGENT; CHLORAMBUCIL; FLUDARABINE; INTERFERON;

ADVANCED CANCER; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISEASE COURSE; EDITORIAL; FOLLICULAR LYMPHOMA; HUMAN; IRRADIATION; META ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RECURRENT CANCER; STEM CELL TRANSPLANTATION; SYSTEMATIC REVIEW; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT PLANNING; NOTE; PATHOLOGY; SURVIVAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; LYMPHOMA, FOLLICULAR; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 24644505859     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.03.911     Document Type: Editorial

References (15)

1. Swenson WT, Wooldridge JE, Lynch CF, et al: Improved survival of follicular lymphoma patients in the United States. J Clin Oncol 23:5019-5026, 2005
2. Lui Q, Fayad L, Hagmeister FB, et al: Stage IV indolent lymphoma: 25 years of treatment progress. Blood 102:398a, 2003 (abstr 1446)
3. Fisher RI, LeBlanc M, Press OW, et al: New treatment options have changed the natural history of follicular lymphoma. Blood 104:168a, 2004 (abstr)
4. Symmers D: Giant follicular lymphadenopathy with or without splenomegaly. Arch Pathol 26:603-647, 1938
5. Gall EA, Mallor TB: Malignant lymphoma: A clinicopathological survey of 618 cases. Am J Pathol 18:381-415, 1942
6. Rosenberg SA, Diamond HD, Craver LF: Lymphosarcoma: Survival and the effects of therapy. Am J Roentgenol Radium Ther Nucl Med 85:521-532, 1961
7. Jones SE, Fuks Z, Bull M, et al: Non-Hodgkin's lymphoma: IV. Clinicopathologic correlation in 405 cases. Cancer 31:806-823, 1973
8. Brice P, Bastion Y, Lepage E, et al: Comparison in low-tumour-burden follicular lymphomas between an initial no treatment policy, prednimustine or interferon-alpha: A randomised study from the Groupe d'Etude des Lymphomas Folliculaires. J Clin Oncol 15:1110-1117, 1997
9. Young R, Longo D, Glatstein E, et al: Watchful waiting vs aggressive combine modality treatment. Semin Hematol 25:11-6, 1988 (2 suppl 2)
10. Advani R, Rosenberg S, Horning S: Stage I and II follicular non-Hodgkin's lymphoma: Long-term follow-up of no initial therapy. J Clin Oncol, 22:1454-1459, 2004
11. Ardeshna KM, Smith P, Norton A, et al: Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced stage non-Hodgkin's lymphoma: A randomised controlled trial. Lancet 362:516-522, 2003
12. Galton DAG, Israels LG, Nabarro JDN, et al: Clinical trial of p(dichloroethylamino) phenylbutyric acid (CB 1348) in malignant lymphoma. BMJ 2:1172-1176, 1955
13. Gallagher CJ, Gregory WM, Jones AE, et al: Follicular lymphoma: Prognostic factors for response and survival. J Clin Oncol 4:1470-1480, 1986
14. Schouten HC, Qianm W, Kvaloym S, et al: High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: Results from the randomised European CUP trial. J Clin Oncol 21:3918-3927, 2003
15. Rohatiner AZS, Gregory WM, Peterson B, et al: Meta-analysis to evaluate the role of interferon in follicular lymphoma. J Clin Oncol 23:2215-2223, 2005